Large multi-center Phase 3 human clinical trials testing efficacy, absolute risk reduction, and adverse-event rates against placebo or active gold-standard comparators. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
The benefit of edoxaban 15 mg was consistent in older adults patients with irregular heartbeat (AFib) and extremely low body weight, though clinicians must remain vigilant about the risk of major bleeding, especially...
Both treatment arms showed similar efficacy among selected populations with high-risk features.
Based on our results, synbiotic had beneficial effects on some pregnancy outcomes.
The Clavien-Dindo classification of adverse event grades revealed no significant differences between HIPEC and controls ( p = 0.482).
HBV-miR-3 is new biomarker for HBV replication and positively correlated to HBV replication.
Fifty-two weeks of mepolizumab treatment is associated with sustained clinical benefits up to 24 weeks after discontinuation in patients with severe CRSwNP, which should be considered.
However, they experienced worsening of diarrhea and/or nausea/vomiting.
The results indicate that the SNaP toothpaste provides a greater level of efficacy in the removal of extrinsic tooth stain as compared to a regular fluoride toothpaste when used twice a day, as measured with Lobene stain.
The secondary endpoints for proportion of patients achieving reduction in HbA1c, glycaemic level and weight, changes in heart and blood vessel parameters and the overall safety profiles of the study drugs were comparable.
JEV-PI is a promising vaccine as infants acquired long-lasting and highly neutralizing immune antibodies after inoculation with JEV-PI.
Pimavanserin was well tolerated and not associated with motor or cognitive impairment.
Conclusions : The aggregate response benefit in skin clearance and itch reduction favored upadacitinib 30 mg over dupilumab and upadacitinib 15 or 30 mg over placebo.
These results indicate a strong association between WMH and MCH, a common manifestation of cerebral amyloid angiopathy and ARIA-H.
Midturbinate swabs yielded a 53% lower viral load versus nasopharyngeal swabs, and this difference was similar for influenza A and B.
Regardless of baseline HbA1c (≤8.5% or >8.5%), tirzepatide at doses of 5, 10 and 15 mg is effective in Japanese patients with T2D compared with dulaglutide 0.75 mg in terms of glycaemic control and body weight reduction, with...
After six years, 44.1% of the cyclophosphamide group scored an SF-36 PF of at least 70, and 17.6% of at least 90, suggesting that cyclophosphamide in a subgroup may modulate the disease course in a beneficial way.
Real-world benefits and safety data support abrocitinib use to manage AD in patients with or without allergic comorbidities.
Low-moderateintensity CIAT-Plus and M-MAT were feasible and acceptable.
The use of remimazolam to achieve sedation in Japanese patients undergoing colonoscopy was more effective than placebo.
This study shows that a DEX-free OPF regimen is efficacious and should be considered a standard option for acute and delayed CINV prophylaxis for HEC.
This early health technology assessment model used inclusion criteria from clinical trials.
Patients initially planned for WP radiation with field decision change to PB-only radiation after PET showed (1) no significant difference in 3-year bRFS compared with patients initially planned for PB-only radiation; and (2)...
The most common AEs in the fostamatinib group were diarrhea (26.7%), high blood pressure (24.4%), and fatigue (15.6%).
In vitro and clinical evaluation results indicate that SNaP is highly effective in coating the dentin surface, occluding exposed dentin tubules, and offering sensitivity relief from the first day of use, a benefit that...
Presence of ADA (with or without NAb) was associated with lower drug concentrations and faster clearance but not with the development of immunologically related AEs.
We plan to enroll 280 patients from 54 institutions over 4 years.
The additional MRSI-guided irradiation dose totaling 72 Gy was well tolerated but did not improve OS in newly diagnosed GBM.
In this first study of a long-acting HIV prevention agent in pregnancy, adverse pregnancy outcomes and complications were uncommon when DVR and TDF/FTC were used in the third trimester of pregnancy, suggesting a favorable...
Three serious side effects (1 in Vi-DT; 2 in Vi-TT group) were reported during the 6 months follow-up, none being related to the investigational product.
Abrocitinib was effective in preventing flare in adolescents and adults.Clinicaltrials.gov listing: NCT03627767.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
